Seeking Alpha

Alexza Pharmaceuticals (ALXA +4.5%) gains on its announcement earlier today that a CHMP Day 180...

Alexza Pharmaceuticals (ALXA +4.5%) gains on its announcement earlier today that a CHMP Day 180 Second List of Outstanding Issues from the European Medicines Agency found no objections regarding its Marketing Authorization Application for its schizophrenia treatment Adasuve. There were two major objections outlined in the CHMP's initial release, which appear to have been resolved. ALXA expects to receive its Day 210 EMA Opinion in December.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|